4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results, Misses Estimates By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) released its quarterly earnings results on Friday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Up 1.1 %

Shares of NASDAQ FDMT opened at $4.53 on Friday. 4D Molecular Therapeutics has a 12 month low of $4.20 and a 12 month high of $36.25. The company has a market cap of $209.41 million, a price-to-earnings ratio of -1.59 and a beta of 2.81. The business has a fifty day simple moving average of $5.22 and a 200-day simple moving average of $8.59.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, February 10th. Morgan Stanley decreased their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Monday, January 13th. Leerink Partners decreased their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.